BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 17186329)

  • 1. Matrix metalloproteinase-2, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in the peripheral blood of patients with various glomerular diseases and their implication in pathogenetic lesions: study based on an enzyme-linked assay and immunohistochemical staining.
    Endo T; Nakabayashi K; Sekiuchi M; Kuroda T; Soejima A; Yamada A
    Clin Exp Nephrol; 2006 Dec; 10(4):253-61. PubMed ID: 17186329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
    Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
    Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of matrix metalloproteinases 2 and 1 in the glomeruli of human glomerular diseases: the results of studies using immunofluorescence, in situ hybridization, and immunoelectron microscopy.
    Sekiuchi M; Kudo A; Nakabayashi K; Kanai-Azuma M; Akimoto Y; Kawakami H; Yamada A
    Clin Exp Nephrol; 2012 Dec; 16(6):863-74. PubMed ID: 22614167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High glucose decreases matrix metalloproteinase-2 activity in rat mesangial cells via transforming growth factor-beta1.
    Singh R; Song RH; Alavi N; Pegoraro AA; Singh AK; Leehey DJ
    Exp Nephrol; 2001; 9(4):249-57. PubMed ID: 11423724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
    Ulrich D; Hrynyschyn K; Pallua N
    Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
    J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and response to angiotensin-converting enzyme inhibition of matrix metalloproteinases 2 and 9 in renal glomerular damage in young transgenic rats with renin-dependent hypertension.
    Bolbrinker J; Markovic S; Wehland M; Melenhorst WB; van Goor H; Kreutz R
    J Pharmacol Exp Ther; 2006 Jan; 316(1):8-16. PubMed ID: 16166267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal expression of matrix metalloproteinases in human ANCA-associated glomerulonephritis.
    Sanders JS; van Goor H; Hanemaaijer R; Kallenberg CG; Stegeman CA
    Nephrol Dial Transplant; 2004 Jun; 19(6):1412-9. PubMed ID: 15034162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
    Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased plasma matrix metalloproteinase-2 (MMP-2), tissue inhibitor of proteinase-1 (TIMP-1), TIMP-2, and urine MMP-2 concentrations correlate with proteinuria in renal transplant recipients.
    Mazanowska O; Zabińska M; Kościelska-Kasprzak K; Kamińska D; Krajewska M; Banasik M; Madziarska K; Zmonarski SC; Chudoba P; Biecek P; Boratyńska M; Klinger M
    Transplant Proc; 2014 Oct; 46(8):2636-9. PubMed ID: 25380883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of MMP-9 in mesangial cells and its changes in anti-GBM glomerulonephritis in WKY rats.
    Kuroda T; Yoshida Y; Kamiie J; Kovalenko P; Nameta M; Fujinaka H; Yaoita E; Endo T; Ishizuka S; Nakabayashi K; Yamada A; Nagasawa T; Yamamoto T
    Clin Exp Nephrol; 2004 Sep; 8(3):206-15. PubMed ID: 15480897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinase, tissue inhibitor of metalloproteinase and transforming growth factor-beta 1 in frozen shoulder, and their changes as response to intensive stretching and supervised neglect exercise.
    Lubis AM; Lubis VK
    J Orthop Sci; 2013 Jul; 18(4):519-27. PubMed ID: 23604641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eosinophil inflammation of nasal polyp tissue: relationships with matrix metalloproteinases, tissue inhibitor of metalloproteinase-1, and transforming growth factor-beta1.
    Lee YM; Kim SS; Kim HA; Suh YJ; Lee SK; Nahm DH; Park HS
    J Korean Med Sci; 2003 Feb; 18(1):97-102. PubMed ID: 12589095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.
    Dellalibera-Joviliano R; Jacob-Ferreira AL; Joviliano EE; Tanus-Santos JE; Evora PR
    Vasc Med; 2012 Apr; 17(2):73-8. PubMed ID: 22402936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
    Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
    Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
    George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
    Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis.
    Akiyama K; Shikata K; Sugimoto H; Matsuda M; Shikata Y; Fujimoto N; Obata K; Matsui H; Makino H
    Res Commun Mol Pathol Pharmacol; 1997 Feb; 95(2):115-28. PubMed ID: 9090749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
    Lorenzl S; Buerger K; Hampel H; Beal MF
    Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma transforming growth factor beta1, metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 in acute viral hepatitis type B.
    Flisiak R; Jaroszewicz J; Lapiński TW; Flisiak I; Rogalska M; Prokopowicz D
    Regul Pept; 2005 Nov; 131(1-3):54-8. PubMed ID: 16081167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic venous insufficiency.
    Saito S; Trovato MJ; You R; Lal BK; Fasehun F; Padberg FT; Hobson RW; Durán WN; Pappas PJ
    J Vasc Surg; 2001 Nov; 34(5):930-8. PubMed ID: 11700497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.